| For: | Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, Sugita M. Angiotensin receptor blocker neprilysin inhibitors. World J Cardiol 2021; 13(8): 325-339 [PMID: 34589168 DOI: 10.4330/wjc.v13.i8.325] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v13/i8/325.htm |
| Number | Citing Articles |
| 1 |
Maya K. Jangid, Gaurav M. Doshi. Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management. Hypertension Research 2025; 48(1) doi: 10.1038/s41440-024-01989-w
|
| 2 |
Vasudeva Reddy Netala, Sireesh Kumar Teertam, Huizhen Li, Zhijun Zhang. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells 2024; 13(17) doi: 10.3390/cells13171471
|
| 3 |
Samah S. Abbas, Mona F. Schaalan, Sahar M. Gebril, Fatma E. Hassan, Maha O. Mahmoud, Soha O. Hassanin. LCZ696 (sacubitril/valsartan) protects against cyclophosphamide-induced nephrotoxicity in adult male rats: Up-regulation of Apelin-13/ACE2, miR-200, and down-regulation of TGF-β/SMAD 2/3 and miR-192. Life Sciences 2022; 306 doi: 10.1016/j.lfs.2022.120850
|
| 4 |
Xiaoye Li, Chengchun Zuo, Can Chen, Dan Tian, Jing Li, Linlin Fan, Xiaoyu Li, Qianzhou Lv. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study. International Journal of Cardiology 2023; 371 doi: 10.1016/j.ijcard.2022.09.050
|
| 5 |
Navya Sakhamuri, Sreekartthik Athiyaman, Bhawna Randhi, Sai Dheeraj Gutlapalli, Jingxiong Pu, Maheen F Zaidi, Maithily Patel, Lakshmi Malvika Atluri, Natalie A Gonzalez, Michael Alfonso. Sacubitril/Valsartan in Heart Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away?. Cureus 2023; doi: 10.7759/cureus.37335
|